Gilead Sciences, Inc. (GILD) Position Cut by Edgewood Management LLC

Gilead Sciences, an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Vetr's price objective points to a potential upside of 11.82% from the stock's current price.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 7th. Maxim Group restated a "hold" rating on shares of Gilead Sciences in a report on Sunday, November 6th.

Gilead Sciences Inc. has dropped 4.08% during the last 3-month period. They issued a "buy" rating and a $88.00 price target on the stock. Van Hulzen Asset Management LLC boosted its stake in shares of Gilead Sciences by 9.1% in the second quarter. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the stock. On a daily basis over the past month, the average true range of the stock, as expressed in percentage terms, is 1.9%. Gilead Sciences has a 12 month low of $65.38 and a 12 month high of $103.10. Company has reported several Insider transactions to the SEC, on Mar 3, 2017, John C Martin (Executive Chairman) sold 73,333 shares at 70.38 per share price.On Feb 27, 2017, Gayle E Wilson (director) sold 20,365 shares at 69.30 per share price.On Nov 22, 2016, John W Madigan (director) sold 105,000 shares at 74.86 per share price.

Gilead Sciences Inc. has a market capital of 89946.17 at the moment and a profit to earnings ratio of 6.94. (NASDAQ:GILD) reported its EPS in the last quarter as $2.7/Share beating the analyst estimate of $2.61/Share by the difference of $0.09. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. Gilead Sciences's revenue was down 13.9% on a year-over-year basis.

Gilead Sciences, Inc is a research-based biopharmaceutical company.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Investors of record on Thursday, March 16th will be given a dividend of $0.52 per share. It has a dividend yield of 3.04%. The ex-dividend date is Tuesday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is now 18.91%. This insider holds 838,652 shares with a market value around $57883761.04 as of recent close. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The firm owned 73,142 shares of the biopharmaceutical company's stock after selling 1,870 shares during the period. The insider owns 1,165,924 shares as of less than 0.1%, now worth $80472074.48. Bank of New York Mellon Corp raised its position in Gilead Sciences by 0.6% in the third quarter. The Manufacturers Life Insurance Company bought a new stake in Gilead Sciences during the third quarter worth about $271,588,000. Platinum Investment Management Ltd. increased its stake in Gilead Sciences by 24.7% in the second quarter. (NASDAQ:GILD) traded with the volume of 8.78 Million in the previous trading session.

Glancing over stock's performance with EPS trend, the current quarter estimates trends for EPS by pool of analysts was $-0.52 and for one month ago was $-0.52, as Q1 2017 Trends estimate stands at $-0.51, according to WSJ analytic reports.

While looking at the Stock's Performance, Gilead Sciences Inc. now shows a Weekly Performance of -0.7%, where Monthly Performance is -3.72%, Quarterly performance is -3.06%, 6 Months performance is -9.38% and yearly performance percentage is -19.57%.

  • Zachary Reyes